Advertisement
DRUG vs IMVT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a StrongBuy and IMVT is a StrongBuy.
DRUG's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for DRUG turned positive on October 07, 2026. Looking at past instances where DRUG's MACD turned positive, the stock continued to rise in 38 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DRUG's RSI Oscillator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRUG advanced for three days, in 157 of 190 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
DRUG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DRUG as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRUG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DRUG entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.722) is normal, around the industry mean (3.037). P/E Ratio (-19.021) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRUG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. DRUG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IMVT in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
IMVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 34 cases where IMVT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Indicator exited the oversold zone, 21 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where IMVT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 204 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for IMVT entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.912) is normal, around the industry mean (3.037). P/E Ratio (-10.025) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IMVT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 62 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 61 | |
P/E GROWTH RATING 1..100 | 17 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| DRUG | IMVT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 90% | N/A |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| Advances ODDS (%) | 8 days ago 83% | 8 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRUG’s FA Score shows that 2 FA rating(s) are green while IMVT’s FA Score has 2 green FA rating(s).
- DRUG’s FA Score: 2 green, 3 red.
- IMVT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRUG’s TA Score shows that 5 TA indicator(s) are bullish while IMVT’s TA Score has 5 bullish TA indicator(s).
- DRUG’s TA Score: 5 bullish, 3 bearish.
- IMVT’s TA Score: 5 bullish, 2 bearish.
Price Growth
DRUG (@Biotechnology) experienced а -5.07% price change this week, while IMVT (@Biotechnology) price change was +1.99% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.61%. For the same industry, the average monthly price growth was -10.44%, and the average quarterly price growth was -13.24%.
Reported Earning Dates
IMVT is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+4.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DRUG and
Correlation & Price change
A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with ACAD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then ACAD could also see price increases.
| Ticker / NAME | Correlation To DRUG | 1D Price Change % | ||
|---|---|---|---|---|
| DRUG | 100% | -2.65% | ||
| ACAD - DRUG | 42% Loosely correlated | +0.05% | ||
| RAPP - DRUG | 41% Loosely correlated | -2.31% | ||
| STOK - DRUG | 39% Loosely correlated | +1.68% | ||
| IMVT - DRUG | 39% Loosely correlated | -0.84% | ||
| BIVI - DRUG | 39% Loosely correlated | +7.26% | ||
More | ||||
IMVT and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | -0.84% | ||
| ROIV - IMVT | 63% Loosely correlated | -1.21% | ||
| KURA - IMVT | 54% Loosely correlated | +0.10% | ||
| LXEO - IMVT | 47% Loosely correlated | -3.57% | ||
| NAMS - IMVT | 45% Loosely correlated | -0.91% | ||
| DYN - IMVT | 45% Loosely correlated | +0.64% | ||
More | ||||